Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Neu Base Therapeutics Inc (NBSE)

Neu Base Therapeutics Inc (NBSE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,501
  • Shares Outstanding, K 3,752
  • Annual Sales, $ 0 K
  • Annual Income, $ -4,370 K
  • 60-Month Beta 0.81
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.17
Trade NBSE with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -7.21
  • Most Recent Earnings $-0.95 on 11/09/23
  • Latest Earnings Date 05/09/24 [--]
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3600 +13.58%
on 05/06/24
0.4653 -12.12%
on 04/15/24
+0.0014 (+0.34%)
since 04/08/24
3-Month
0.3600 +13.58%
on 05/06/24
1.1500 -64.44%
on 03/20/24
-0.2611 (-38.97%)
since 02/08/24
52-Week
0.3600 +13.58%
on 05/06/24
4.8000 -91.48%
on 05/22/23
-3.3871 (-89.23%)
since 05/08/23

Most Recent Stories

More News
SYMETRYX CORPORATION ACQUIRES 20% STOCK IN NEUBASE

/PRNewswire/ - Today, Symetryx Corporation ("Symetryx") announced that it has acquired 20% of the issued and outstanding common stock in Neubase Therapeutics...

NBSE : 0.4089 (+2.22%)
SYMETRYX CORPORATION ACQUIRES 20% STOCK IN NEUBASE

/CNW/ - Today, Symetryx Corporation ("Symetryx") announced that it has acquired 20% of the issued and outstanding common stock in Neubase Therapeutics Inc....

NBSE : 0.4089 (+2.22%)
What Makes NeuBase (NBSE) a New Strong Buy Stock

NeuBase (NBSE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

NBSE : 0.4089 (+2.22%)
Best Momentum Stocks to Buy for January 20th

NBSE, PRTG and NOMD made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 20, 2022.

NOMD : 17.85 (+0.68%)
NBSE : 0.4089 (+2.22%)
PRTG : 0.2919 (-6.95%)
New Strong Buy Stocks for January 20th

NBSE, PRTG, RELL, HOWL and PATH have been added to the Zacks Rank #1 (Strong Buy) List on January 20, 2022.

RELL : 10.83 (+1.12%)
PATH : 19.90 (-0.60%)
NBSE : 0.4089 (+2.22%)
PRTG : 0.2919 (-6.95%)
HOWL : 5.48 (-4.20%)
NeuBase (NBSE) Up on Restructuring Plan, Set to Lower Workforce

NeuBase (NBSE) intends to reduce its existing workforce by nearly 60%. The company plans to maximize shareholder value and focus on the advancement of its platform in gene editing. Stock up.

ACAD : 17.13 (-0.70%)
AGLE : 12.01 (+8.79%)
NBSE : 0.4089 (+2.22%)
ORIC : 9.60 (-0.10%)
NeuBase Therapeutics Reports Business Update and Financial Results for the Third Quarter of Fiscal Year 2022

Lead myotonic dystrophy type 1 (DM1) candidate continues to show promising preclinical data, including the pharmacokinetics (PK) and biodistribution data...

NBSE : 0.4089 (+2.22%)
NeuBase Therapeutics Announces Promotion of Dr. William Mann to President and COO

PITTSBURGH and CAMBRIDGE, Mass., June 29, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a...

NBSE : 0.4089 (+2.22%)
NeuBase to Participate at the Jefferies Healthcare Conference

PITTSBURGH and CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a...

NBSE : 0.4089 (+2.22%)
NeuBase Therapeutics Reports Business Update and Financial Results for the Second Quarter of Fiscal Year 2022

Investigational New Drug (IND)-enabling studies continue to generate promising data that support further development of the company’s lead myotonic...

NBSE : 0.4089 (+2.22%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

NeuBase Therapeutics Inc. is a biotechnology company. It is engaged in developing antisense therapies to address genetic diseases. The company's proprietary platform includes PATrOL(TM). NeuBase Therapeutics Inc., formerly known as Ohr Pharmaceutical Inc., is based in Pittsburgh, United States.

See More

Key Turning Points

3rd Resistance Point 0.4602
2nd Resistance Point 0.4349
1st Resistance Point 0.4219
Last Price 0.4089
1st Support Level 0.3836
2nd Support Level 0.3583
3rd Support Level 0.3453

See More

52-Week High 4.8000
Fibonacci 61.8% 3.1039
Fibonacci 50% 2.5800
Fibonacci 38.2% 2.0561
Last Price 0.4089
52-Week Low 0.3600

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar